Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06547216 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
A Phase 2 study, sponsored by Avidity Biosciences.
- Active
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT06547216 is a Phase 2 study that is active but no longer recruiting, run by Avidity Biosciences. The registered enrollment target is 84 participants.
The verdict
NCT06547216, a Phase 2 study, is active but no longer recruiting, sponsored by Avidity Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions
- DRUG AOC 1020
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2024-07-25 |
| Est. Completion | 2030-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06547216
The ClinicalTrials.gov registry entry for NCT06547216 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avidity Biosciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AOC 1020 is the first listed.
NCT06547216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06547216 about?
NCT06547216 is a clinical study titled "Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)". A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
What is the current status of trial NCT06547216?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2024-07-25. Estimated completion is 2030-06.
What interventions are being tested in trial NCT06547216?
The interventions under investigation include: AOC 1020 (DRUG).
Who is sponsoring clinical trial NCT06547216?
This trial is sponsored by Avidity Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.